Literature DB >> 32816173

High Prevalence of Cervical High-Risk Human Papillomavirus Harboring Atypical Genotypes in Human Immunodeficiency Virus -Infected and -Uninfected First-Generation Adult Immigrant Women Originating from Sub-Saharan Africa and Living in France.

Ralph-Sydney Mboumba Bouassa1,2,3,4, Camelia Gubavu5, David Veyer1,2, Leman Robin1,2, Anne Gravier5, Laurent Hocqueloux5, Thierry Prazuck5, Hélène Péré1,2,4, Laurent Bélec6,7,8.   

Abstract

Human papillomavirus (HPV)-related cervical lesions in first-generation immigrant African women in France should reflect the epidemiology of high-risk (HR)-human papillomavirus (HPV) infection in sub-Saharan Africa. First-generation immigrant African women attending the Centre Hospitalier Régional of Orléans, France, were prospectively subjected to endocervical swabs for HPV DNA PCR and Pap smear. Fifty women (mean age, 41.7 years) living in France (mean stay, 10.7 years) were enrolled, including 26.0% of HIV-negative women from general population and 74.0% of women with known HIV infection. Cervical HPV prevalence was 68.0%, with 56.0% of HR-HPV. HR-HPV -68 and -58 were the predominant genotypes (20.0% and 14.0%, respectively). HR-HPV-16 and HR-HPV-18 were infrequently detected. HIV-infected women showed a trend to be more frequently infected by HPV than HIV-negative women (70.3% versus 61.5%). Most women (84.0%) showed normal cytology, while the remaining (16.0%) exhibited cervical abnormalities and were frequently HIV-infected (87.5%). These observations highlight the unsuspected high burden of cervical HR-HPV infections mostly associated with atypical genotypes, HIV infection and cervical abnormalities in first-generation immigrant African women living in France.

Entities:  

Keywords:  Cervical cancer; First-generation; France; Human immunodeficiency virus; Human papillomavirus; Immigrant women; Sub-saharan africa

Year:  2021        PMID: 32816173      PMCID: PMC7914190          DOI: 10.1007/s10903-020-01074-7

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  54 in total

1.  Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Authors:  S Rachel Skinner; Anne Szarewski; Barbara Romanowski; Suzanne M Garland; Eduardo Lazcano-Ponce; Jorge Salmerón; M Rowena Del Rosario-Raymundo; René H M Verheijen; Swee Chong Quek; Daniel P da Silva; Henry Kitchener; Kah Leng Fong; Céline Bouchard; Deborah M Money; Arunachalam Ilancheran; Margaret E Cruickshank; Myron J Levin; Archana Chatterjee; Jack T Stapleton; Mark Martens; Wim Quint; Marie-Pierre David; Dorothée Meric; Karin Hardt; Dominique Descamps; Brecht Geeraerts; Frank Struyf; Gary Dubin
Journal:  Lancet       Date:  2014-09-01       Impact factor: 79.321

2.  Prevalence of human papillomavirus infection in Italian and immigrant women.

Authors:  P Paba; G Morosetti; A A Criscuolo; V Chiusuri; F Marcuccilli; F Sesti; E Piccione; C F Perno; M Ciotti
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Oct-Dec       Impact factor: 3.219

3.  Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.

Authors:  Helena Faust; Lars Toft; Peter Sehr; Martin Müller; Jesper Bonde; Ola Forslund; Lars Østergaard; Martin Tolstrup; Joakim Dillner
Journal:  Vaccine       Date:  2016-02-16       Impact factor: 3.641

Review 4.  The HIV Epidemic: High-Income Countries.

Authors:  Sten H Vermund; Andrew J Leigh-Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

5.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

6.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.

Authors:  Laia Bruni; Mireia Diaz; Xavier Castellsagué; Elena Ferrer; F Xavier Bosch; Silvia de Sanjosé
Journal:  J Infect Dis       Date:  2010-11-10       Impact factor: 5.226

7.  Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.

Authors:  C Clavel; M Masure; J P Bory; I Putaud; C Mangeonjean; M Lorenzato; P Nazeyrollas; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

8.  Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.

Authors:  Mark H Einstein; Myron J Levin; Archana Chatterjee; Nahida Chakhtoura; Peter Takacs; Grégory Catteau; Francis J Dessy; Philippe Moris; Lan Lin; Frank Struyf; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Age-specific prevalence of human papilloma virus infection among Nigerian women.

Authors:  Sally N Akarolo-Anthony; Ayo O Famooto; Eileen O Dareng; Olayinka B Olaniyan; Richard Offiong; Cosette M Wheeler; Clement A Adebamowo
Journal:  BMC Public Health       Date:  2014-06-27       Impact factor: 3.295

10.  Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial.

Authors:  K Haguenoer; S Sengchanh; C Gaudy-Graffin; J Boyard; R Fontenay; H Marret; A Goudeau; N Pigneaux de Laroche; E Rusch; B Giraudeau
Journal:  Br J Cancer       Date:  2014-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.